Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tertomotide - KAEL-GemVax

Drug Profile

Tertomotide - KAEL-GemVax

Alternative Names: GV1001; hTERT RNA vaccine - KAEL-GemVax; LucaVax; Telomerase peptide vaccine - KAEL-GemVax; TeloVac

Latest Information Update: 10 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmexa
  • Developer Affitech A/S; Cancer Research UK; KAEL-GemVax; Lytix Biopharma; Norwegian Radium Hospital; Pharmexa
  • Class Cancer vaccines; Peptide fragments; Ribonucleoproteins
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase II Alzheimer's disease; Benign prostatic hyperplasia; Non-small cell lung cancer
  • Phase I/II Malignant melanoma
  • No development reported Solid tumours
  • Discontinued Liver cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Apr 2018 The South Korean regulatory authority and regulatory authorities from other countries approve the initiation of two phase III trial in Benign prostatic hyperplasia
  • 16 Apr 2018 KAEL-GemVax plans a phase III global trial for Benign prostatic hyperplasia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top